- Sections
- C - Chimiemétallurgie
- C07C - Composés acycliques ou carbocycliques
- C07C 251/32 - Oximes
Détention brevets de la classe C07C 251/32
Brevets de cette classe: 30
Historique des publications depuis 10 ans
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Ambrx, Inc. | 181 |
7 |
| University of Southampton | 443 |
2 |
| BASF SE | 20912 |
1 |
| The Regents of the University of California | 19887 |
1 |
| AstraZeneca AB | 2923 |
1 |
| AstraZeneca UK Limited | 650 |
1 |
| Syngenta Crop Protection AG | 6057 |
1 |
| Shin-Etsu Chemical Co., Ltd. | 5644 |
1 |
| Advansix Resins & Chemicals LLC | 299 |
1 |
| Cognis IP Management GmbH | 634 |
1 |
| GE Healthcare Limited | 673 |
1 |
| Guangzhou Magpie Pharmaceutical Co., Ltd | 1 |
1 |
| Kyung Nong Corporation | 15 |
1 |
| Oak Ridge National Laboratory | 3 |
1 |
| Screen Holdings Co., Ltd. | 2804 |
1 |
| Universidad de Leon | 26 |
1 |
| Universidad Publica de Navarra | 49 |
1 |
| The University of Melbourne | 536 |
1 |
| University of Tennessee Research Foundation | 759 |
1 |
| University of Virginia Patent Foundation | 1569 |
1 |
| Autres propriétaires | 3 |